Ashok C et al (2021) E2F1 and epigenetic modifiers orchestrate breast cancer progression by regulating oxygen-dependent ESRP1 expression. Oncogenesis 10(8):58

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bai X et al (2022) Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade. J Exp Clin Cancer Res 41(1):132

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boguslawska J et al (2016) microRNAs target SRSF7 splicing factor to modulate the expression of osteopontin splice variants in renal cancer cells. Gene 595(2):142–149

Article  CAS  PubMed  Google Scholar 

Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424

Article  PubMed  Google Scholar 

Cavaloc Y et al (1994) Characterization and cloning of the human splicing factor 9G8: a novel 35 kDa factor of the serine/arginine protein family. Embo J 13(11):2639–2649

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Z, Hu H (2019) Identification of prognosis biomarkers of prostatic cancer in a cohort of 498 patients from TCGA. Curr Probl Cancer 43(6):100503

Article  PubMed  Google Scholar 

Chen J et al (2017) Identification of a DNA damage-induced alternative splicing pathway that regulates p53 and cellular senescence markers. Cancer Discov 7(7):766–781

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen SH et al (2021) Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity. J Immunother Cancer 9(10):e003464

Cheng F et al (2018) Capn4 promotes colorectal cancer cell proliferation by increasing MAPK7 through activation of the Wnt/β-Catenin pathway. Exp Cell Res 363(2):235–242

Article  CAS  PubMed  Google Scholar 

Coulie PG et al (2014) Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14(2):135–146

Article  CAS  PubMed  Google Scholar 

Cun Y et al (2021) Specific regulation of m(6)A by SRSF7 promotes the progression of Glioblastoma. Genom Proteom Bioinform. https://doi.org/10.1016/j.gpb.2021.11.001

Doak GR, Schwertfeger KL, Wood DK (2018) Distant relations: macrophage functions in the metastatic niche. Trends Cancer 4(6):445–459

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Miguel FJ et al (2014) Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer. Cancer Res 74(4):1105–1115

Article  PubMed  Google Scholar 

Esfahani K et al (2020) A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol 27(Suppl 2):S87-s97

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fu Y, Wang Y (2018) SRSF7 knockdown promotes apoptosis of colon and lung cancer cells. Oncol Lett 15(4):5545–5552

PubMed  PubMed Central  Google Scholar 

Galiana-Arnoux D et al (2003) The CD44 alternative v9 exon contains a splicing enhancer responsive to the SR proteins 9G8, ASF/SF2, and SRp20. J Biol Chem 278(35):32943–32953

Article  CAS  PubMed  Google Scholar 

Hepatocellular carcinoma (2021) Nat Rev Dis Primers 7(1):7

Article  Google Scholar 

Howard JM, Sanford JR (2015) The RNAissance family: SR proteins as multifaceted regulators of gene expression. Wiley Interdiscip Rev RNA 6(1):93–110

Article  CAS  PubMed  Google Scholar 

Huang Y, Steitz JA (2005) SRprises along a messenger’s journey. Mol Cell 17(5):613–615

Article  CAS  PubMed  Google Scholar 

Jiang Y et al (2019) Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature 567(7747):257–261

Article  CAS  PubMed  Google Scholar 

Jin Y et al (2019) MicroRNA 32 promotes cell proliferation, migration, and suppresses apoptosis in colon cancer cells by targeting OTU domain containing 3. J Cell Biochem 120(11):18629–18639

Article  CAS  PubMed  Google Scholar 

Königs V et al (2020) SRSF7 maintains its homeostasis through the expression of Split-ORFs and nuclear body assembly. Nat Struct Mol Biol 27(3):260–273

Article  PubMed  PubMed Central  Google Scholar 

Le QV et al (2019) Nanomaterials for modulating innate immune cells in cancer immunotherapy. Asian J Pharm Sci 14(1):16–29

Article  PubMed  Google Scholar 

Liu J et al (2020) Identification of a prognostic signature of epithelial ovarian cancer based on tumor immune microenvironment exploration. Genomics 112(6):4827–4841

Article  CAS  PubMed  Google Scholar 

Liu J et al (2021) Comprehensive of N1-Methyladenosine modifications patterns and immunological characteristics in Ovarian Cancer. Front Immunol 12:746647

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu C et al (2022) A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy. Nat Nanotechnol 17(5):531–540

Article  CAS  PubMed  Google Scholar 

Liu J et al (2022) Pyroptosis-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with UCEC. Mol Ther Nucleic Acids 27:1036–1055

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mair F et al (2022) Extricating human tumour immune alterations from tissue inflammation. Nature 605(7911):728–735

Article  CAS  PubMed  PubMed Central  Google Scholar 

Manley JL, Krainer AR (2010) A rational nomenclature for serine/arginine-rich protein splicing factors (SR proteins). Genes Dev 24(11):1073–1074

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nair M, Sandhu SS, Sharma AK (2018) Cancer molecular markers: a guide to cancer detection and management. Semin Cancer Biol 52(Pt 1):39–55

Article  CAS  PubMed  Google Scholar 

Nevola R et al (2023) Predictors of early and late hepatocellular carcinoma recurrence. World J Gastroenterol 29(8):1243–1260

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oshida K et al (2011) Novel gene markers of immunosuppressive chemicals in mouse lymph node assay. Toxicol Lett 205(1):79–85

Article  CAS  PubMed  Google Scholar 

Park WC et al (2016) Comparative expression patterns and diagnostic efficacies of SR splicing factors and HNRNPA1 in gastric and colorectal cancer. BMC Cancer 16:358

Article  PubMed  PubMed Central  Google Scholar 

Raponi M et al (2011) Prediction of single-nucleotide substitutions that result in exon skipping: identification of a splicing silencer in BRCA1 exon 6. Hum Mutat 32(4):436–444

Article  CAS  PubMed  Google Scholar 

Reimand J et al (2019) Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap. Nat Protoc 14(2):482–517

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tam BY et al (2020) The CLK inhibitor SM08502 induces anti-tumor activity and reduces wnt pathway gene expression in gastrointestinal cancer models. Cancer Lett 473:186–197

Article  CAS  PubMed  Google Scholar 

Tan W, Wang W, Ma Q (2018) Physiological and pathological function of serine/arginine-rich splicing factor 4 and related diseases. Biomed Res Int 3819719:1–9

ten Dam GB et al (2000) Regulation of alternative splicing of CD45 by antagonistic effects of SR protein splicing factors. J Immunol 164(10):5287–5295

Article  PubMed  Google Scholar 

van Roosmalen W et al (2015) Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant. J Clin Invest 125(4):1648–1664

Article  PubMed  PubMed Central  Google Scholar 

Wang ZW et al (2022) SRSF3-mediated regulation of N6-methyladenosine modification-related lncRNA ANRIL splicing promotes resistance of pancreatic cancer to gemcitabine. Cell Rep 39(6):110813

Article  CAS  PubMed  Google Scholar 

Wu J et al (2021) A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarc